TITLE

Drug safety alert issued for dronedarone

PUB. DATE
September 2011
SOURCE
Travel Medicine Advisor;Sep2011 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the Food and Drug Administration (FDA) has issued a drug safety alert for dronedarone on July 21, 2011 in relation to the PALLAS sponsored study which shows the high mortality rate in patients with atrial fibrillation (AF) associated to the said drug.
ACCESSION #
65173889

 

Related Articles

  • FDA actions. Elliott, William T. // Travel Medicine Advisor;Feb2012 Supplement, p1 

    The article offers news briefs related to U.S. Food and Drug Administration (FDA) which includes the approval of generic atorvastatin, the approval of Prevnar 13 and the prescription of Dronedarone to patients with permanent atrial fibrillation (AF).

  • Dabigatran for stroke in patients with nonvalvular atrial fibrillation. Elliott, William T. // Infectious Disease Alert;Apr2011 Pharmacology Watch, p1 

    The article focuses on direct thrombin inhibitor Dabigatran that has been approved for preventing stroke in patients who have nonvalvular atrial fibrillation. It mentions that rivaroxaban, a direct factor Xa inhibitor is still in the process of gaining the U.S. Food and Drug Administration's...

  • Dronedarone Approved.  // Infectious Disease Alert;Sep2009 Pharmacology Watch, p2 

    The article reports on the approval of anti-arrhythmic dronedarone drug by the U.S. Food and Drug Administration (FDA). Dronedarone is prescribed to patients with a history of atrial fibrillation for the maintenance of normal sinus rhythm. The approval was based on the trial conducted by FDA on...

  • Dabigatran for stroke in patients with nonvalvular atrial fibrillation. Elliott, William T. // Neurology Alert;Apr2011 Clinical Bri, p1 

    The article reports on the U.S. Food and Drug Administration (FDA) approval gained by dabigatran, a direct thrombin inhibitor, for prevention of stroke in patients with nonvalvular atrial fibrillation. Also, the American College of Cardiology, the American Heart Association and the Heart Rhythm...

  • Determining Which Anti-Clotting Drug is Best Suited for You.  // Women's Health Advisor;Feb2014, Vol. 18 Issue 2, p3 

    The article discusses the comparison between anti-clotting drugs, warfarin and novel oral anticoagulants (NOAs), used by atrial fibrillation (AF) patients and approved by the U.S. Food and Drug Administration. A brief overview on the working of anticoagulants is offered. Topics discussed include...

  • Atritech files PMA for its Watchman LAA closure device for AF. PEDERSEN, AMANDA // Cardiovascular Devices & Drugs;Sep2008, Vol. 14 Issue 9, p26 

    The article reports on the application by Atritech of a pre-market approval (PMA) application with the U.S. Food and Drug Administration (FDA) for its Watchman Left Atrial Appendage (LAA) closure device. The product is intended to keep dangerous blood clots from entering a patient's blood stream...

  • Positive Outcome After Intentional Overdose of Dabigatran. Woo, Jason; Kapadia, Neel; Phanco, Sarah; Lynch, Catherine // Journal of Medical Toxicology;Jun2013, Vol. 9 Issue 2, p192 

    Introduction: Dabigatran (Pradaxaâ„¢), an orally active direct thrombin inhibitor, was approved by the United States Food and Drug Administration for the prevention of stroke in patients with atrial fibrillation in October 2010. Life-threatening consequences from dabigatran therapy include...

  • Ryan L. Thompson of Watts Guerra Craft LLP Moves to Consolidate Pradaxa Lawsuits in MDL No. 2385.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article informs that an oral argument by Ryan L. Thompson of Watts Guerra Craft LLP will be conducted in front of the U.S. Judicial Panel on Multi District Litigation (JMPL) on July 26, 2012 in Cleveland, Ohio. It further informs that the U.S. Food and Drug Administration has approved...

  • PRODUCT BRIEFS.  // Medical Device Daily;5/19/2008, Vol. 12 Issue 96, p11 

    This section offers news briefs on the medical instruments industry in the U.S. as of May 19, 2008. The Food and Drug Administration (FDA) has cleared the iFS advanced femtosecond laser of Advanced Medical Optics. The results of the phase II coronary revascularization trial conducted by Biopure...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics